Another UK snub: Cambridge spin-out eyes New York IPO as unicorn status beckons January 29, 2024 Life sciences startup Nuclera has said it is eyeing up a public listing in New York in the next five years as it approaches unicorn status.
Tribunal upholds £84m CMA fine for firm that hiked drug prices August 8, 2023 The companies behind a drug whose price was hiked from £20 to £248 per pack in just eight years will be fined a combined £84 million after a tribunal upheld the competition watchdog’s decision. The Competition Appeal Tribunal on Tuesday had endorsed “all the main elements” of the Competition and Markets Authority’s decision, the CMA [...]
Pfizer’s revenue drops over 50 per cent as Covid-19 vaccine sales wither August 1, 2023 US drugmaker Pfizer today reported that revenue more than halved during the second quarter of the year as global demand for its Covid-19 vaccines plummeted. It reported disappointing revenues of $12.7bn (£9.9bn) in the three months April to June – down 54 per cent, or $15bn, from the second quarter last year. Pfizer blamed the [...]
GSK brings in zosta lot more cash as drugs giant’s turnover boosted by shingles vaccine and HIV medicines April 26, 2023 Drugs giant GSK has posted better-than-forecast revenues for the first quarter thanks to strong sales of its shingles vaccine and HIV medicines. The FTSE 100 group saw earnings fall 15 per cent on a constant currency basis to £2.1bn in the first quarter as revenues dropped eight per cent to £7bn after sales of its Covid-19 treatment [...]
GSK coughs up £1.6bn for Bellus as pharma giant boosts its patent medicine cabinet April 18, 2023 GSK plans to buy developer Bellus Health in an all-cash deal for £1.6bn as the drugmaker expands its bet on respiratory therapies.
Astrazeneca’s shares rise, as cancer drug uptake offsets fall in sales of pharma giant’s Covid-19 vaccine February 9, 2023 Astrazeneca has posted what it claimed were “strong” financial results for the full year 2022 as surging demand for cancer medicines offset a fall in Covid vaccine revenues. Shares in Astrazeneca jumped on the news as the firm said it expects another year of double-digit revenue growth in 2023. The British firm’s strong results came [...]
Warning of Lemsip, cough and cold medicine shortage as Brits battle winter flu January 4, 2023 Brits are struggling to get hold of cough and cold medicine as a nasty strain of flu sweeps the nation. It has been reported that there is a shortage of medicines such as throat lozenges, cough mixtures, Lemsip powders and pain killers. This comes after the UK Health and Security Agency issued a warning about [...]
Eyes peeled: Five technologies to watch next year December 27, 2022 The year of the Great Tech Sell-Off is coming to a close. But in this Digital Age, technology is only going to get more exciting, useful, and ethically questionable – so here’s five technologies to watch out for next year. SOLAR Solar power is becoming cheaper, more efficient and increasingly attractive for Brits looking to [...]
Drug developer files patents for cancer treatment which ‘outperforms’ AstraZeneca offering December 20, 2022 Drug development company Nuformix has reformulated and improved one of AstraZeneca’s top cancer drugs, piquing investor interest today. Shares in the London-listed firm jumped nearly a quarter to 35p per share by early afternoon on Tuesday. Nuformix, which focuses on fibrosis and cancer drug repurposing, announced that the drug, known as Olaparib, had “outperformed” AstraZeneca’s [...]
European regulator injects hope into AstraZeneca’s bid to tackle cancer December 19, 2022 The European Medicines Agency has handed AstraZeneca a number of recommendations and one approval for a trio of cancer drugs the Big Pharma firm is looking to market in the continent. AstraZeneca’s cancer drug Enhertu has been given the green light by the European regulator for use among patients with gastric cancer. Around 136,000 cases [...]